Prospective Catalystem CT-RSA
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Canadian Radiostereometric Analysis Network
- Trial code
- NCT07698717
- Record updated
- 13 July 2026
- Original description
Multi-Centre Study in patients undergoing Total Hip Arthroplasty with the Smith+Nephew CATALYSTEM™ Primary Hip System. The primary objective is to establish the mean inferior stem migration (subsidence) of the CATALYSTEM™ stem using CT-RSA over the first two postoperative years.Read full original descriptionShow less
Multi-center, Non-controlled, Prospective CT-based Radiostereometric Analysis of Catalystem Primary Hip System
Multi-Centre Study in patients undergoing Total Hip Arthroplasty with the Smith+Nephew CATALYSTEM™ Primary Hip System. The primary objective is to establish the mean inferior stem migration (subsidence) of the CATALYSTEM™ stem using CT-RSA over the first two postoperative years.
Inclusion: Patient requires primary unilateral THA for a severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, avascular necrosis, or congenital dysplasia; Patients is at least 21 years old at the time of informed consent; Patient is able to read and comprehend the informed patient consent document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information for study purposes; Patient is able and willing to return for follow-up as specified by the study protocol; Patient is able and willing to complete the required questionnaires and patient-completed portions of the study protocol.
Exclusion: Patient requires implants other than the planned components or would not be a candidate for allowable components to be used (see 4) in the judgement of the surgeon; Patient had contralateral hip arthroplasty less than 6 months prior to the day of surgery; Patient has amputations in either leg that would impact rehabilitation following surgery; Patient has loss of musculature, neuromuscular compromise or vascular compromise that would impact rehabilitation following surgery; Patient has poor bone quality, such as osteoporosis, where in the surgeon's opinion, there could be considerable migration of the prosthesis, or require additional fixation, or a significant chance of periprosthetic fracture, or the lack of adequate bone to support the implant(s); Patient has participated in a clinical investigation with an investigational product (drug or device) in the last 3 months; Patient has active local or systemic infection; Patient has Charcot's or Paget's disease; Patients is, in the opinion of the surgeon, a drug or alcohol abuser or has psychological disorder(s) that could affect their ability to complete patient-reported questionnaires or be compliant with follow-up requirements; Patient is diagnosed and taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia; Patient is planned to have simultaneous bilateral hip arthroplasty; Patient is expected to have contralateral hip arthroplasty in the following 6 months at the time of consent into this study; Patient is pregnant or lactating; Patient is bedridden; Patient is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.